Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.neclife.com | |
Market Cap | 764.06 Cr. | |
Enterprise Value(EV) | 1,446.45 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.36 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 94.57 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.03 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 47.67 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 0.71 | Calculated using Price: 34.07 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 22.43 Cr. | 224,260,970 Shares |
FaceValue | 1 | |
About Nectar Lifesciences Ltd. | ||
Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv Goyal. |
1 Day |
|
+2.50% |
1 Week |
|
+2.05% |
1 Month |
|
+10.81% |
3 Month |
|
+3.11% |
6 Month |
|
+54.89% |
1 Year |
|
+100.29% |
2 Year |
|
+12.60% |
5 Year |
|
+107.44% |
10 Year |
|
+22.07% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 7.17 | 5.78 | 5.64 | 5.06 | 4.4 | 2.84 | -6.67 | 2.33 | -2.25 | |
Return on Capital Employed (%) | 11.58 | 9.95 | 9.73 | 9.13 | 10.29 | 8.32 | 1.41 | 5.77 | 1.97 | |
Return on Assets (%) | 2.7 | 2.14 | 2.15 | 1.97 | 1.75 | 1.19 | -2.93 | 1.05 | -1.06 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 958 | 954 | 1,007 | 1,059 | 1,105 | 1,136 | 1,062 | 1,088 | 1,065 | 1,067 | |
Non Curr. Liab. | 397 | 362 | 296 | 356 | 300 | 249 | 126 | 296 | 213 | 172 | |
Curr. Liab. | 1,156 | 1,240 | 1,279 | 1,309 | 1,300 | 1,248 | 1,187 | 1,004 | 891 | 885 | |
Minority Int. | |||||||||||
Equity & Liab. | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,124 | |
Non Curr. Assets | 1,106 | 1,092 | 1,085 | 1,063 | 1,036 | 1,018 | 1,137 | 1,033 | 937 | 916 | |
Curr. Assets | 1,369 | 1,464 | 1,496 | 1,661 | 1,669 | 1,615 | 1,239 | 1,355 | 1,231 | 1,208 | |
Misc. Exp. not W/O | 36 | ||||||||||
Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,124 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 1,644 | 1,676 | 1,644 | 1,876 | 2,783 | 2,366 | 1,543 | 1,669 | 1,524 | 1,633 | |
Other Income | 20 | 6 | 23 | 6 | 6 | 4 | 11 | 11 | 43 | 29 | |
Total Income | 1,664 | 1,681 | 1,666 | 1,882 | 2,789 | 2,371 | 1,555 | 1,680 | 1,567 | 1,663 | |
Total Expenditure | -1,377 | -1,437 | -1,419 | -1,640 | -2,519 | -2,147 | -1,442 | -1,510 | -1,471 | -1,510 | |
PBIDT | 287 | 245 | 247 | 242 | 270 | 224 | 113 | 170 | 96 | 152 | |
Interest | -126 | -123 | -117 | -115 | -148 | -126 | -112 | -79 | -79 | -83 | |
Depreciation | -77 | -57 | -62 | -64 | -63 | -61 | -60 | -57 | -59 | -61 | |
Taxation | -18 | -10 | -12 | -10 | -11 | -6 | 12 | -9 | 18 | -1 | |
Exceptional Items | -25 | ||||||||||
PAT | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 8 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | 1 | ||||||||||
Consolidated Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 8 | |
Adjusted EPS | 3 | 2 | 2 | 2 | 2 | 1 | -3 | 1 | -1 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 255 | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | |
Cash Fr. Inv. | -90 | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | |
Cash Fr. Finan. | -161 | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | |
Net Change | 4 | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | |
Cash & Cash Eqvt | 10 | 33 | 37 | 13 | 9 | 21 | 21 | 26 | 18 | 18 |
Wed, 17 Apr 2024
Updates Nectar Lifesciences Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 '. |
Mon, 08 Apr 2024
Disclosure under SEBI Takeover Regulations ᅡᅠSanjiv Goyal self and Karta of Sanjiv (HUF)has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaᅡᅠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011 |
Sat, 06 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Nectar Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
Tue, 23 Apr 2024 |
High Increase in 1 Month |
High Increase in 6 Months |
High Increase in 1 Year |
High Increase in 5 Years |
RSI Trending Down |